Estimates Revisions Monte Rosa Therapeutics, Inc.
Stocks
GLUE
US61225M1027
Biotechnology & Medical Research
|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 15.45 USD | -6.48% |
|
-30.90% | -0.57% |
| 07-31 | Novo Nordisk Shares Sink After Heart Disease Drug Candidate Fails Late-Stage Trial | MT |
| 07-31 | Wedbush Adjusts Monte Rosa Therapeutics Price Target to $27 From $37, Maintains Outperform Rating | MT |
Turnover - Evolution of Analysts' Estimates
Earnings Per Share (EPS) - Evolution of Analysts' Estimates
EBIT - Evolution of Analysts' Estimates
| 1m. Revenue rev. | 1y. Revenue rev. | 1y. EPS revision | ||
|---|---|---|---|---|
 | ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| ||||
| - | |||
| ||||
| ||||
| Average | ||||
| Weighted average by Cap. |
Turnover
Earnings Per Share (EPS)
EBIT
- Stock Market
- Stocks
- GLUE Stock
- Consensus Monte Rosa Therapeutics, Inc.
- Estimates Revisions
Select your edition
All financial news and data tailored to specific country editions
